OptiNose

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OptiNose prioritizes XHANCE launch for sinusitis, eyes growth opportunities

OptiNose is focusing on profitability and preparing for the launch of XHANCE for chronic sinusitis, anticipating improved financial performance in 2023.
The company's strategic initiatives include exploring commercial partnerships, optimizing expenses, and evaluating potential sale options, indicating a proactive approach to growth.
While facing challenges in revenue generation and prescription volumes, OptiNose is leveraging strengths in financial stability, market reach, and growth opportunities.

OptiNose reports steady Q1 performance amidst revenue challenges and growth opportunities

OptiNose's Q1 2023 performance showed steady prescription demand and a strategic focus on profitability and growth.
While facing challenges like revenue decline and sales force impact, the company is poised for opportunities in market expansion and successful product launches.
Overall, OptiNose remains optimistic about meeting expectations and future approval, positioning itself for continued success in the pharmaceutical market.

OptiNose reports steady Q2 performance, eyes growth with new indications

OptiNose's Q2 2023 performance showed stable prescription demand and a strategic focus on the potential launch of a chronic sinusitis treatment in 2024.
While facing challenges like slightly lower net revenue and upcoming operating expenses, the company is well-positioned for growth opportunities.
With raised revenue guidance, a clear operating strategy, and ongoing FDA review, OptiNose is poised for potential revenue expansion and market growth.

OptiNose reports stable Q3 revenue, eyes growth through XHANCE launch

OptiNose's Q3 2023 performance showed stability in revenue and improved cost efficiency.
While facing challenges in prescription numbers, the company is strategically positioned for growth.
Opportunities lie in potential market expansion through new indications and partnerships.

OptiNose reports strategic growth in Q4 2023, eyes XHANCE approval

OptiNose's performance in Q4 2023 showcased progress in key areas, with a strategic focus on growth and efficiency. The company's financials reflected a reduction in expenses and a stable product demand, positioning it well for potential XHANCE approval and revenue expansion.

OptiNose reports strong Q1 performance and outlines growth strategies

OptiNose's Q1 2024 performance reflects growth in XHANCE net revenue and a strengthened financial position.
The company's strategic focus on chronic sinusitis launch and improved base business fundamentals bode well for future growth.
Opportunities lie in expanding sales efforts, international partnerships, and new product development for sustained value creation.

OptiNose reports Q3 revenue growth, adjusts full-year guidance

OptiNose's Q3 performance showed revenue growth and strategic adjustments.
While challenges like conservative guidance were raised, opportunities for growth exist.
Management's focus on execution and communication bodes well for future prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

YARDLEY, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer.

Optinose Appoints Paul Spence as Chief Commercial Officer

YARDLEY, Pa., Dec. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Michele Janis, Acting Chief Financial Officer, will leave Optinose to accept a CFO opportunity at a privately-held company. Ms. Janis will continue to serve as Acting Chief Financial Officer until her departure on December 30, 2022.

Optinose Announces Departure of Acting Chief Financial Officer

$50 Million from Recent Financing Extends Expected Cash Runway Beyond the Expected PDUFA Action Date for XHANCE as a Treatment for Chronic Sinusitis

Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and warrants to purchase 26,320,000 shares of its common stock at a combined public offering price of $1.90 per share and accompanying warrant, for gross proceeds of approximately $50 million to Optinose, before deducting underwriting discounts and commissions and offering expenses payable by Optinose. All shares of common stock and accompanying warrants in the offering are being offered by Optinose. The offering is expected to close on or about November 23, 2022, subject to the satisfaction of customary closing conditions.

Optinose Announces Pricing of Public Offering of Common Stock and Warrants

YARDLEY, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of common stock in an underwritten public offering. All shares of common stock and accompanying warrants to be sold in the offering will be sold by Optinose. In addition, Optinose is expected to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the total number of shares of common stock and/or warrants to purchase shares of common stock to be offered at the public offering price, less the underwriting discount. The public offering price has not yet been determined. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Optinose Announces Proposed Public Offering of Common Stock and Warrants

OptiNose, Inc. (NASDAQ:OPTN ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Jonathan Neely - VP, IR and Business Development Peter Miller - CEO Ramy Mahmoud - President and COO Conference Call Participants Glenn Santangelo - Jefferies Isaac Somekh - Piper Sandler Gary Nachman - BMO Capital Markets Stacy Ku - Cowen Brandon Folkes - Cantor Jonathan Neely [Starts Abruptly] Third quarter 2022 performance and our plans for the remainder of the year. I'm joined today by our CEO, Peter Miller; our President and Chief Operating Officer, Dr. Ramy Mahmoud; and our Chief Commercial Officer, Victor Clavelli.

OptiNose, Inc. (OPTN) Q3 2022 Earnings Call Transcript

OptiNose (OPTN) delivered earnings and revenue surprises of -5.88% and 17.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q3 Loss, Misses Revenue Estimates

YARDLEY, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen2 phase 3 clinical trial will be presented at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting in Louisville, Kentucky on November 12, 2022.

Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting

Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held November 10, 2022, at 8:00 a.m. Eastern Time

Optinose Announces Reporting Date for Third Quarter 2022 Financial Results

Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial program

Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022

ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical Rhinology ReOpen1 Phase 3 Clinical Trial Chosen as a Top-Rated Abstract in Clinical Rhinology

Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting

OptiNose, Inc. (NASDAQ:OPTN ) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Ramy Mahmoud - President and COO Vic Clavelli - Chief Commercial Officer Conference Call Participants Brandon Folkes - Cantor Gary Nachman - BMO Capital Markets Stacy Ku - Cowen Operator Good day, and thank you for standing by. Welcome to the OptiNose's Second Quarter 2022 Earnings Call.

OptiNose, Inc. (OPTN) CEO Peter Miller on Q2 2022 Results - Earnings Call Transcript

OptiNose (OPTN) delivered earnings and revenue surprises of -4.55% and 7.70%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q2 Loss, Misses Revenue Estimates

Company reports second quarter XHANCE net revenue of $20.6 million increased 12%

Optinose Reports Second Quarter 2022 Financial Results and Operational Updates

Conference Call and Webcast to be held August 11, 2022, at 8:00 a.m. Eastern Time Conference Call and Webcast to be held August 11, 2022, at 8:00 a.m. Eastern Time

Optinose Announces Reporting Date for Second Quarter 2022 Financial Results

XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trials to reduce exacerbations for patients with chronic sinusitis

Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program

Company previously announced positive top-line results from both ReOpen1 and ReOpen2, the landmark trials evaluating XHANCE as a treatment for chronic sinusitis

Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program

OptiNose's revenue was $14.8 million in the first quarter, up 23.3% year-over-year. The company has published the results of two Phase 3 clinical trials that met both primary and secondary endpoints.

OptiNose: Potential Winner In Chronic Sinusitis Treatment

Applied UV

Clovis Oncology

Hut 8 Mining Corp

Penny Stocks To Watch Right Now The post Best Penny Stocks To Buy Now? 4 To Watch After June's Fed Meeting appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy Now? 4 To Watch After June's Fed Meeting

Optinose Inc (NASDAQ: OPTN) announced the statistically significant benefits of XHANCE in the ReOpen2 trial for the symptoms co-primary endpoint and the CT scan co-primary endpoint.  Significant improvement was seen in patients with chronic sinusitis who did not have nasal.

Optinose Stock Moves Higher On Positive Second Chronic Sinusitis Phase 3 Trial

First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients

Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

Michele Janis Appointed Acting Chief Financial Officer

Optinose Announces Departure of Chief Financial Officer

OptiNose, Inc. (NASDAQ:OPTN ) Q1 2022 Earnings Conference Call May 12, 2022 8:00 AM ET Company Participants Jonathan Neely - IR Peter Miller - CEO Keith Goldan - CFO Vic Clavelli - Chief Commercial Officer Ramy Mahmoud - President and COO Conference Call Participants Stacey Ku - Cowen Dave Amsellem - Piper Sandler Gary Nachman - BMO Capital Markets Brandon Folkes - Cantor Fitzgerald Operator Good day, and thank you for standing by. Welcome to the OptiNose First Quarter 2022 Earnings Conference Call.

OptiNose, Inc. (OPTN) CEO Peter Miller on Q1 2022 Results - Earnings Call Transcript

OptiNose (OPTN) delivered earnings and revenue surprises of -29.17% and 12.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

OptiNose (OPTN) Reports Q1 Loss, Misses Revenue Estimates

Company reports first quarter XHANCE net revenue of $14.8 million increased 35% compared to first quarter 2021

News for OptiNose Stock (OPTN)